Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Scheduled to Reverse Split on Tuesday, April 23rd

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s stock is scheduled to reverse split before the market opens on Tuesday, April 23rd. The 1-80 reverse split was announced on Tuesday, April 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd.

Pieris Pharmaceuticals Trading Down 6.6 %

Shares of NASDAQ:PIRS traded down $0.01 during trading on Friday, reaching $0.15. 1,919,826 shares of the company traded hands, compared to its average volume of 580,219. The firm has a market capitalization of $14.34 million, a price-to-earnings ratio of -0.52 and a beta of 0.48. Pieris Pharmaceuticals has a 52-week low of $0.14 and a 52-week high of $1.01. The business’s fifty day moving average is $0.17 and its 200-day moving average is $0.20.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.05) earnings per share for the quarter. The company had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative return on equity of 90.17%.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Pieris Pharmaceuticals in a research note on Saturday, April 13th. They set a “hold” rating for the company.

Institutional Trading of Pieris Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. Acadian Asset Management LLC raised its holdings in Pieris Pharmaceuticals by 64.8% in the third quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock worth $286,000 after purchasing an additional 378,339 shares in the last quarter. CM Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 18.1% during the third quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 99,400 shares in the last quarter. UBS Group AG bought a new position in shares of Pieris Pharmaceuticals during the first quarter valued at $67,000. Hsbc Holdings PLC increased its holdings in shares of Pieris Pharmaceuticals by 55.6% during the first quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 7,343 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Pieris Pharmaceuticals during the third quarter valued at $60,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.